investigating the effect of atorvastatin on the cisplatin induced nephrotoxicity

Phase 3

Recruiting

• Conditions: Cisplatin nephrotoxicity.; Acute kidney failure, unspecified; N17.9

• Registration Number: IRCT20140605017982N2
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

New cases of patients with solid tumors under Cisplatin therapy,
minimum age of 18
glomerular filtration rate( GFR) > 60 ml/min
serum creatinine less than 1.5 mg/dl

Exclusion Criteria

Patients who used cisplatin less than 50mg/m2 or divided dose of cisplatin in several days
patients with a past history of Cisplatin therapy, chronic kidney disease, NSAIDS usage or using any nephrotoxic drugs will not participate in this study
patients with a history of NSAIDS usage or using any nephrotoxic drugs will not participate in this study
patients with a historyof chronic kidney disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of people with renal failure. Timepoint: measurement of blood Urea nitrogen, creatinine, potassium, magnesium before intervention and 8 and 21 days after intervention. Method of measurement: measurement of blood Urea nitrogen, creatinine, potassium, magnesium.